Post by miamianne67 on Nov 17, 2016 21:54:32 GMT
Under the global movement of foreign governments pressuring pharma to cut even better deals and offer drugs cheaper overseas coupled with the current political rhetoric on both sides of the aisle in the US especially post Valeant, how does Opko see this atmosphere as effecting it's projected bottom line and R & D. Thank you, Miami
